Advancement in the Treatment of Recurrent Pericarditis: Exploring Innovative Therapeutic Options.

Abstract

Acute pericarditis, the predominant pericardial disease, often lacks a clear etiology, with 15-30% of patients experiencing recurrence, rising to 20-50% in those with prior relapses. Autoimmune mechanisms significantly contribute to recurrence, with interleukin-1 identified as a pivotal inflammatory mediator. While NSAIDs, colchicine, and steroids remain staples for acute cases, the spotlight in recurrent pericarditis management has shifted toward immunosuppressive medications. Pericardiectomy serves as the ultimate resort. Notably, rilonacept emerges as a key player, specifically addressing cases resistant to colchicine and dependent on corticosteroids in recurrent pericarditis.